SOFIA CHAGOLLAN: Open Payments
NPI 1841988086 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,735 in 81 payments from 15 companies in 2025. Trend: 2023 $917 · 2024 $2,154 · 2025 $1,735
Food & beverage: $1,735
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $679 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $199 |
| Janssen Biotech, Inc. | 7 | $169 |
| Madrigal Pharmaceuticals | 5 | $110 |
| Ardelyx, Inc. | 5 | $99 |
| Gilead Sciences, Inc. | 4 | $79 |
| Braintree Laboratories, Inc. | 3 | $76 |
| Lilly USA, LLC | 3 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Biocon Biologics Inc | 2 | $46 |
Products named: SKYRIZI, LINZESS, TREMFYA, RINVOQ, CREON, XIFAXAN, REZDIFFRA, IBSRELA.
Industry payments across TX — which companies pay providers there.
